Results 81 to 90 of about 4,800,081 (359)

Persistent HIV-1 replication during antiretroviral therapy

Current Opinion in HIV and AIDS, 2016
Purpose of reviewThe present review will highlight some of the recent findings regarding the capacity of HIV-1 to replicate during antiretroviral therapy (ART).
J. Martinez-Picado, S. Deeks
semanticscholar   +1 more source

Treatment outcomes from the largest antiretroviral treatment program in Myanmar (Burma): a cohort analysis of retention after scale-up. [PDF]

, 2012
Article approval pendingAntiretroviral treatment (ART) coverage in Myanmar is well below average. This study describes retention and baseline predictors of prognosis from the largest ART program in the ...
Bisson, Braitstein, Brinkhof, Brinkhof, Chi, Coetzee, Cornell, Deeks, Egger, Ferradini, Ferradini, Fox, Frank Smithuis, Ivers, Kalpana Sabapathy, Kazatchkine, Keiser, Khin Nyein Chan, Komatsu, Madec, McGuire, Moe Kyaw Kyaw, Nathan Ford, Riekje Elema, Sian Floyd, Thai, Van Cutsem, Williams, Zachariah, Zachariah, Zhang   +30 more
core   +2 more sources

Drug Discovery Applications of Nitroso (Hetero)Arene Derivatives

ChemPlusChem, EarlyView.
Nitroso (hetero)aromatic compounds are bioactive molecules with antiviral, anticancer, neuroprotective, and antimicrobial properties. This review highlights their mechanisms of action—oxidative stress, DNA damage, and enzyme inhibition—alongside synthesis, structure–activity relationships, and toxicity challenges, offering insight into their ...
Silvia Roscales, Aurelio G. Csáky
wiley   +1 more source

Assessment of antiretroviral therapy knowledge and willingness of persons with HIV to support its uptake in Uganda

Patient Preference and Adherence, 2011
Richard Batamwita1, David M Moore2, Rachel King3, Edward Mills4, Anne L Stangl5 1Mildmay Centre, Kampala, Uganda; 2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada; 3Karolinska Institute, Stockholm, Sweden; 4University of Ottawa ...
Batamwita R, Moore DM, King R, Mills E, Stangl AL   +4 more
doaj  

Management of Reduced Bone Mineral Density in HIV: Pharmacological Challenges and the Role of Exercise

Frontiers in Physiology, 2018
Low bone mineral density is becoming more common among people living with HIV following the use of current antiretroviral therapy drugs such as tenofovir.
Enock M. Chisati, Demitri Constantinou, Fanuel Lampiao   +2 more
doaj   +1 more source

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

International Journal of Cancer, EarlyView.
What's New? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar, Paula Lakrout, Valérie Potard, Aurélien Belot, Jacques Cadranel, Christine Jacomet, Christine Katlama, Esaïe Marshall, Olivier Lambotte, Romain Palich, Sylvie Ronot‐Bregigeon, Jean‐Philippe Spano, Anne‐Marie Bouvier, Alain Makinson, Dominique Costagliola   +14 more
wiley   +1 more source

Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004–12: a prospective cohort study

The Lancet Global Health, 2014
Background: Studies of HIV-serodiscordant couples in stable sexual relationships have provided convincing evidence that antiretroviral therapy can prevent the transmission of HIV.
Alain Vandormael, MS, Prof. Marie-Louise Newell, PhD, Till Bärnighausen, MD, Prof. Frank Tanser, PhD   +3 more
doaj   +1 more source

Rapamycin limits CD4+ T cell proliferation in simian immunodeficiency virus–infected rhesus macaques on antiretroviral therapy [PDF]

, 2022
Benjamin D Varco-Merth, William Brantley, Alejandra Marenco, Derick D. Duell, Devin N Fachko, Brian Richardson, Kathleen Busman-Sahay, Danica Shao, Walter Flores, Kathleen Engelman, Yoshinori Fukazawa, Scott W Wong, Rebecca L Skalsky, Jeremy Smedley, Michael K. Axthelm, Jeffrey D. Lifson, Jacob D Estes, Paul T Edlefsen, Louis J. Picker, Cheryl M.A. Cameron, Timothy J Henrich, Afam A Okoye, Benjamin D Varco-Merth, William Brantley, Alejandra Marenco, Derick D. Duell, Devin N Fachko, Brian Richardson, Kathleen Busman-Sahay, Danica Shao, Walter Flores, Kathleen Engelman, Yoshinori Fukazawa, Scott W Wong, Rebecca L Skalsky, Jeremy Smedley, Michael K. Axthelm, Jeffrey D. Lifson, Jacob D Estes, Paul T Edlefsen, Louis J. Picker, Cheryl M.A. Cameron, Afam A Okoye   +42 more
openalex   +1 more source

Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia [PDF]

, 2011
Objectives  To report immunovirological outcomes and resistance patterns in adults treated with triple combination antiretroviral therapy (cART) for 4 years in an HIV programme of Phnom Penh, Cambodia.
Balkan, Suna, Chanchhaya, Ngeth, Ferradini, Laurent, Narom, Prak, Nerrienet, Eric, Pujades-Rodríguez, Mar, Schramm, Birgit, Som, Leakena   +7 more
core   +2 more sources

Exposure–Response Modeling and Simulation to Identify Optimal Mavacamten Posology When Coadministered with CYP3A4 and CYP2C19 Inhibitors in Patients with Obstructive HCM

The Journal of Clinical Pharmacology, EarlyView.
Abstract Mavacamten, a cardiac myosin inhibitor, is primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2C19 and CYP3A4, and coadministration with strong CYP3A4 or CYP2C19 inhibitors was contraindicated in patients with obstructive hypertrophic cardiomyopathy (HCM) in the US Prescribing Information. This study assessed the safety and efficacy
Samira Merali, Haden Bunn, Caroline Sychterz, Manting Chiang, Shilpa Puli, Amy J. Sehnert, Bindu Murthy, Joga Gobburu   +7 more
wiley   +1 more source